• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

  • — 16 Nov, 2007
Jean-Yves Douillard
Jean-Yves Douillard
Gordon McVie
Gordon McVie

REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JEAN-YVES DOUILLARD, Centre René Gauducheau, Nante
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

The vinca alkaloid vinflunine and the tyrosine kinase inhibitor gefitinib both achieved equivalent benefits to standard docetaxel second-line therapy among patients with advanced or metastatic non-small cell lung cancer previously treated with platinum.

Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

John Crown
John Crown

Lapatinib Adds Benefit to Capecitabine in Metastatic Breast Cancer

REFERENCE: Abstract: 2096, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JOHN CROWN, St Vincent’s University Hospital, Dublin
In heavily pre-treated metastatic breast cancer, lapatinib has been confirmed to add a benefit to capecitabine, according to updated efficacy data presented in Barcelona. The implication is that gene profiles from some breast tumors could help pinpoint which patients might do best on lapatinib.

Rob Tollenaar
Rob Tollenaar
Gordon McVie
Gordon McVie

Gene Profile to Improve Recommendations in Stage II Colon Cancer?

REFERENCE: Abstract: 3007, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
ROB TOLLENAAR, Leiden University Medical Center
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

The ECCO conference heard that a gene expression profile could help doctors easily identify patients with stage II colon cancer who need chemotherapy after surgery, and might be better at selecting patients for chemotherapy than the current ASCO guidelines.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

You may also like...

  • HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation HAND2 gene: key to endometrial, ovarian cancer detection and treatment individualisation 15 Jan, 2014
  • Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations? Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations? 27 Apr, 2009
  • Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin Esophageal Cancer Prevented By Proton Pump Inhibitor Plus Aspirin 15 Aug, 2018
  • Bevacizumab: New Standard for Non-Small Cell Lung Cancer? Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008
  • Previous story Protective Cardiovascular Benefit for Women on HRT For Natural Menopause
  • Next story Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • New Front Line Standard for Older Patients with Chronic…
    • CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second…
    • Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per…
  • Home
  • Oncology
  • Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.